NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ZOTA · data 2026-10-31
Zota Health Care Ltd.
In plain words
Price: 23.6% below its 52-week high of ₹1,740.
Delivery: 59.3% of traded shares were kept for delivery over the last 10 sessions, against 57.3% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹679 cr |
| Net profit (last 12 months) | ₹-113 cr |
| Sales growth, 3 years (yearly) | 56.9% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 49.4% (-6.4 pts in a year), pledged 0.3%, institutions 14.2%.
ROE -16.1%, ROCE -9.7%, operating margin -15.6%: how much profit it earns on the money it uses.
Debt/equity 0.39, Profit growth — and sales growth 56.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-16.1%).
- Thin operating margin (-15.6%).
- Promoters have pledged 0.3% of their shares.
- Promoters cut their holding by 6.4 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
16/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 11/30: Delivery 57.4% over the last 20 sessions vs 49.0% in the 40 before (1.17x); shares delivered per day 0.86x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 21 Sept 26Dividend Dividend ₹1 (ex-date) +18.5% next session
- 22 Sept 25Dividend Dividend ₹1 (ex-date) +1.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 49.38% | 49.38% | 49.38% | 50.64% |
| Foreign institutions (FII) | 6.92% | 7.92% | 8.21% | 8.09% |
| Domestic institutions (DII) | 7.30% | 6.75% | 6.40% | 7.22% |
| Mutual funds | 0.37% | 0.37% | 0.37% | 0.42% |
| Retail investors | 12.75% | 12.24% | 12.19% | 12.10% |
| Number of shareholders | 14,928 | 14,678 | 14,005 | 13,185 |
Common questions
How much do promoters hold in Zota Health Care Ltd.?
Promoters held 49.38% of Zota Health Care Ltd. at the end of Sept 2026, with 0.26% of promoter shares pledged.
Is Zota Health Care Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.39.
What is the 52-week high and low of Zota Health Care Ltd.?
The 52-week high is ₹1,740 and the 52-week low is ₹1,022.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Zota Health Care Ltd. | ₹1,328.8 | ₹4,031 cr | — | 7.4 | -16.1% | -9.7% | 0.39 | -15.4% |
| RPG Life Sciences Limited | ₹2,575.7 | ₹4,255 cr | 35.6 | — | 20.3% | 21.3% | 0.03 | +5.3% |
| Evonile Pharma Limited | ₹1,692.4 | ₹4,182 cr | 42.7 | — | 11.6% | 11.8% | 0 | +144.9% |
| Gufic Biosciences Limited | ₹413.55 | ₹4,134 cr | 56.5 | — | 10.1% | 15.3% | 0.61 | +23.7% |
| Aarti Drugs Limited | ₹435.2 | ₹3,977 cr | 20.8 | — | 13.4% | 13.2% | 0.37 | -12.1% |
| Kwality Pharmaceuticals Ltd | ₹3,475.3 | ₹3,604 cr | 44.5 | — | 22.6% | 31.4% | 0.39 | +98.9% |
Compare ZOTA with RPGLIFE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ZOTA in NSE Scanner →